A proposal for staging COVID‐19 coagulopathy

Coronavirus disease 2019 (COVID‐19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for...

Full description

Saved in:
Bibliographic Details
Published inResearch and practice in thrombosis and haemostasis Vol. 4; no. 5; pp. 731 - 736
Main Authors Thachil, Jecko, Cushman, Mary, Srivastava, Alok, Angchaisuksiri, Pantep
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2020
Elsevier Limited
John Wiley and Sons Inc
Elsevier
Subjects
Anticoagulants
anticoagulation
Contraindications
Coronaviruses
COVID-19
Cytokine storm
Cytokines
Defects
Embolisms
Forum
Inflammation
Intensive care
Ischemia
Laboratories
Lungs
Mortality
Patients
Studies
Thromboembolism
Thrombosis
United States > US
COVID‐19
thrombosis
anticoagulation
Online AccessGet full text
ISSN2475-0379
2475-0379
DOI10.1002/rth2.12372

Cover

More Information
Summary:Coronavirus disease 2019 (COVID‐19) is associated with significant hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with this condition develop thromboses. This forum discusses the lungs as the epicenter for the hemostatic issues, puts forward a proposal for staging COVID‐19 coagulopathy based on available diagnostic markers, and suggest considering current and future treatment options based on these different stages.
Bibliography:Handling Editor: Pantep Angchaisuksiri
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2475-0379
2475-0379
DOI:10.1002/rth2.12372